Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,494.46
    -1,693.02 (-3.37%)
     

  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

U.S. clears AstraZeneca over heart drug trial

Reuters - UK Focus

LONDON, Aug 19 (Reuters) - AstraZeneca (NYSE: AZN - news) said on Tuesday the U.S. government was closing a probe into a major clinical trial used to win marketing approval for its new heart drug Brilinta and no further action was planned.

The decision last October by the U.S. Department of Justice to investigate the study cast doubts over the future of the medicine, which AstraZeneca argues is a potential $3.5 billion-a-year seller but which has so far registered only modest sales.

AstraZeneca flagged up the promise of Brilinta in its defence against an abortive $118 billion takeover bid by Pfizer earlier this year. (Reporting by Ben Hirschler; Editing by David Holmes)